About Haley Chartres

This author has yet to write their bio.
Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 141 entries.

Entries by Haley Chartres

Capital Raise Update

Botanix has announced it has now closed the first tranche of its anticipated $7.5 million placement to new and existing institutional and sophisticated investors. The second tranche of the Placement is an issue of New Shares to Botanix directors, who have  committed to subscribe for a total of $0.5 million of New Shares, which is […]

$7.5m Capital Raise

Botanix has today announced it has received strong commitments to raise $7.5m through a placement to Australian and international institutions and sophisticated investors. Funds will support the development of the Company’s lead asset – Sofpironium Bromide (SB) – a novel dermatology asset with positive Phase 3 data to treat primary axillary hyperhidrosis, a medical condition […]

Research Report by Euroz Hartleys – 17 August 2022

Botanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has released an analysis outlining the strong market opportunities for our most recent asset acquisition, Sofpironium Bromide. Within the report, analyst Seth Lizee commented: “Sofpironium Bromide’s target patient population is estimated to be ~3.7 million people in the United States, equal to the estimated […]

Euroz Hartleys Report | 7 July 22

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company announcement that the FDA filing timeline for Sofpironium Bromide had been accelerated. Click here to view the report.

NDA filing accelerated and trials fully enrolled

Botanix has today announced the New Drug Approval (NDA) submission to the FDA for our recently acquired dermatology asset, Sofpironium Bromide for the treatment of excessive underarm sweating, will now be ready to file in Q3 2022. The Company also provided an update on its pipeline clinical studies. Both the rosacea (BTX1702) Phase 1/2 clinical […]

Herald Sun + Daily Telegraph | Sofpironium Bromide Story

🗞 MAKING HEADLINES Herald Sun Reporter, Owen Leonard, met with Botanix executives while they were in Australia this week and has published a story about the Company’s recent acquisition of Sofpironium Bromide. This novel potential treatment for primary axillary hyperhidrosis, a medical condition that results in excessive underarm sweat, is bringing new hope for sufferers. […]

Investor Webinar | May 2022

Botanix Pharmaceuticals (ASX: BOT) hosted an investor update webinar following the announcement of its acquisition of Sofpironium Bromide, the first and only novel treatment for primary axillary hyperhidrosis. Present on the call was President and Executive Chairman, Vince Ippolito; Executive Director, Matt Callahan; Chief Medical Adviser, Dr Patricia Walker; and Chief Commercial Officer, Howie McKibbon.